AbbVie follows Gilead in throwing Xilio a lifeline.

The deal isn’t done, but would be Merck’s biggest oncology buy.

Padcev still looks good in first-line bladder, but Pfizer hopes to make a mark in muscle-invasive disease.

Orca-T is said to hit in a pivotal trial, but the comparator regimen could be debated.

The company heralds a pivotal win with its menin inhibitor, but investors want to see data.

While Bicycle clings to the hope of first-line treatment, Innate eyes a post-Padcev fast track.